-
Founded in:
1995-09-28 -
Country:
China -
Address:
Hongbo Industrial Zone, Boluo County -
Tax NO.:
914413001961374115 -
Registered Funds:
102 million yuan -
Website:
-
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Erythromycin Estolate |
This product belongs to the macrolide antibiotics, which is the dodecyl sulfate of erythromycin propionate. It has antibacterial activity against Staphylococcus, various groups of streptococci and Gram-positive bacilli. Neisseria, Haemophilus influenzae, Bordetella pertussis, etc. may also be sensitive to this product. This product also has antibacterial activity against various anaerobic bacteria except Bacteroides fragilis and Fusobacterium; it also has inhibitory effects on Legionella, Campylobacter fetus, some spirochetes, Mycoplasma pneumoniae, Rickettsia and Chlamydia. This product is an antibacterial agent, but it also has a bactericidal effect on some bacteria at high concentrations. This product can pass through the bacterial cell membrane and reversibly bind to the 50S subunit of the bacterial ribosome near the donor site (P site), blocking the transfer RNA (t-RNA) binding to the P site, and also blocking the displacement of the polypeptide chain from the acceptor site (A site) to the P site, thereby inhibiting bacterial protein synthesis. This product is only effective against bacteria with active division.
More
This product belongs to the macrolide antibiotics, which is the dodecyl sulfate of erythromycin propionate. It has antibacterial activity against Staphylococcus, various groups of streptococci and Gram-positive bacilli. Neisseria, Haemophilus influenzae, Bordetella pertussis, etc. may also be sensitive to this product. This product also has antibacterial activity against various anaerobic bacteria except Bacteroides fragilis and Fusobacterium; it also has inhibitory effects on Legionella, Campylobacter fetus, some spirochetes, Mycoplasma pneumoniae, Rickettsia and Chlamydia. This product is an antibacterial agent, but it also has a bactericidal effect on some bacteria at high concentrations. This product can pass through the bacterial cell membrane and reversibly bind to the 50S subunit of the bacterial ribosome near the donor site (P site), blocking the transfer RNA (t-RNA) binding to the P site, and also blocking the displacement of the polypeptide chain from the acceptor site (A site) to the P site, thereby inhibiting bacterial protein synthesis. This product is only effective against bacteria with active division. |
3521-62-8 | 24 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Ofloxacin |
This product has a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative bacilli. It has good antibacterial activity in vitro against the following bacteria: most bacteria of the Enterobacteriaceae family, including Citrobacter, Enterobacter cloacae, Enterobacter aerogenes, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. It often has antibacterial activity against multi-drug resistant bacteria. It has high antibacterial activity against penicillin-resistant Neisseria gonorrhoeae, enzyme-producing Haemophilus influenzae and Moraxella. It has antibacterial activity against most strains of Pseudomonas such as Pseudomonas aeruginosa. This product has antibacterial activity against methicillin-sensitive Staphylococcus aureus, and only moderate antibacterial activity against Streptococcus pneumoniae, hemolytic Streptococcus and Enterococcus faecalis. It has good antimicrobial activity against Chlamydia trachomatis, Mycoplasma, Legionella, and also has antibacterial activity against Mycobacterium tuberculosis and atypical mycobacteria. Poor antibacterial activity against anaerobic bacteria. Ofloxacin is a bactericide that acts on the A subunit of bacterial DNA helicase, inhibiting DNA synthesis and replication, leading to bacterial death.
More
This product has a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative bacilli. It has good antibacterial activity in vitro against the following bacteria: most bacteria of the Enterobacteriaceae family, including Citrobacter, Enterobacter cloacae, Enterobacter aerogenes, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. It often has antibacterial activity against multi-drug resistant bacteria. It has high antibacterial activity against penicillin-resistant Neisseria gonorrhoeae, enzyme-producing Haemophilus influenzae and Moraxella. It has antibacterial activity against most strains of Pseudomonas such as Pseudomonas aeruginosa. This product has antibacterial activity against methicillin-sensitive Staphylococcus aureus, and only moderate antibacterial activity against Streptococcus pneumoniae, hemolytic Streptococcus and Enterococcus faecalis. It has good antimicrobial activity against Chlamydia trachomatis, Mycoplasma, Legionella, and also has antibacterial activity against Mycobacterium tuberculosis and atypical mycobacteria. Poor antibacterial activity against anaerobic bacteria. Ofloxacin is a bactericide that acts on the A subunit of bacterial DNA helicase, inhibiting DNA synthesis and replication, leading to bacterial death. |
82419-36-1 | 30 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Ursodeoxycholic acid |
By inhibiting the reabsorption of cholesterol in the intestine and reducing the secretion of cholesterol into the bile, the saturation of cholesterol in the bile is reduced. Cholesterol stones may be gradually dissolved due to the dispersion of cholesterol and the formation of liquid crystals. The treatment of liver and cholestatic diseases is mainly based on the relative replacement of lipophilic, detergent-like toxic bile acids by hydrophilic, cytoprotective and non-cytotoxic ursodeoxycholic acid, as well as the promotion of hepatocyte secretion and immunomodulation.
More
By inhibiting the reabsorption of cholesterol in the intestine and reducing the secretion of cholesterol into the bile, the saturation of cholesterol in the bile is reduced. Cholesterol stones may be gradually dissolved due to the dispersion of cholesterol and the formation of liquid crystals. The treatment of liver and cholestatic diseases is mainly based on the relative replacement of lipophilic, detergent-like toxic bile acids by hydrophilic, cytoprotective and non-cytotoxic ursodeoxycholic acid, as well as the promotion of hepatocyte secretion and immunomodulation. |
128-13-2 | 40 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Bupleurum |
No specific pharmacological information is provided
More
No specific pharmacological information is provided |
0 |